Zai Lab Ltd. 9688

SHANGHAI & CAMBRIDGE, Mass., September 29, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that global data from a clinical trial evaluating zocilurtatug pelitecan (zoci, formerly ZL-1310) for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) will be shared for the first time at the European Society for Medical Oncology (ESMO) Congress 2026 taking place October 23-27, 2026, in Madrid.

Asian equities traded in the US as American depositary receipts were heading lower in Thursday tradi

Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from.

Big Pharma firms have cut license deals worth tens of billions of dollars for cancer drugs invented in China.

Zai Lab stock presents a challenging valuation picture for investors, with a share price that has risen in the shorter term but sits against a five year record of heavy value loss and only a mixed read from broader valuation checks. The share price has fallen 80.9% over the past five years, which points to a significant destruction of shareholder value over a full market cycle. Future revenue growth from its biopharmaceutical portfolio can support the current valuation, while ongoing...

Asian equities traded in the US as American depositary receipts were edging lower Friday morning, de

Asian equities traded in the US as American depositary receipts were tracking higher Wednesday morni

Asian equities traded in the US as American depositary receipts started the week lower Monday mornin

Asian equities traded in the US as American depositary receipts were rising sharply Friday morning,

Asian equities traded in the US as American depositary receipts were tracking higher Tuesday morning

Zai Lab Limited American Depositary Shares (NASDAQ:ZLAB) and argenx SE (NASDAQ:ARGX) announced positive topline results on August 17 from their Phase 3 ALKIVIA study evaluating VYVGART Hytrulo in adults with autoimmune myositis. In the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population, patients treated with efgartigimod achieved a statistically significant, 15.4-point greater improvement in […]

Dublin, Aug. 20, 2026 (GLOBE NEWSWIRE) -- The "Global DLL3 Targeted Therapies Market Opportunity, Approved Therapy Sales, Pricing, Proprietary Development Platforms & Clinical Trials Insight 2030" has been added to ResearchAndMarkets.com's offering. Key Report Highlights: Global DLL3 targeted therapies market opportunity projected to exceed USD 2 billion by 2030Analysis of current market trends, growth drivers and future commercial opportunitiesUnited States expected to dominate market sales, wh

Asian equities traded in the US as American depositary receipts were tracking modestly higher Wednes

Dr. Charuworn’s extensive immunology drug development experience will help accelerate the clinical development of Coultreon’s first-in-class SIK3 inhibitor COL-5671 Leuven, Belgium. August 18, 2026. Coultreon Biopharma, a clinical-stage biotechnology company developing best-in-class immunology therapies, today announced the appointment of Prista Charuworn, MD, as Chief Medical Officer. Dr. Charuworn completed fellowships in gastroenterology and transplant hepatology at Stanford and has extensive

SHANGHAI & CAMBRIDGE, Mass. & AMSTERDAM, August 17, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & NASDAQ: ARGX), today announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with autoimmune myositis.

Asian equities traded in the US as American depositary receipts were marginally higher Thursday morn

Zoci advances toward global registrational trials as net product revenue rises 11%.

Asian equities traded in the US as American depositary receipts were edging slightly lower Tuesday m

Zai Lab Limited reported second-quarter 2026 results showing revenue of US$106.31 million versus US$109.98 million a year earlier, with net loss widening to US$50.83 million from US$40.73 million and basic loss per share increasing to US$0.50 from US$0.40. Over the first half of 2026, revenue slipped to US$205.92 million while net loss deepened to US$101.84 million, suggesting higher costs or investment needs are weighing more heavily on the income statement than a year ago. We will now...